unknown
Stage
About
Graegis Pharmaceuticals develops topical therapies using reactive-oxygen species scavengers to prevent and manage radiation-induced dermatitis and oral mucositis in oncology patients.
Explore Graegis Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.